Jamieson is delighted to announce that it has advised the management teams of BPL and Kedrion in connection with their acquisitions and subsequent combination by Permira.
The combination of BPL and Kedrion creates a global player for medicinal products derived from human blood plasma, which treat patients with rare and life-threatening conditions. The business has strong established positions in the US, Italy and the UK, with a portfolio of 37 life-saving products reaching over 100 countries. The Permira funds, will support the combined company to grow organically through the internationalisation of its existing portfolio and the acceleration of new product development, as well as pursuing inorganic growth opportunities to become a further diversified and specialist rare disease platform.
The Jamieson team was led by Jonny Jones alongside Fionn Dillon Kelly. The Jamieson team advised both the BPL management team and the Kedrion management team on the new incentive arrangements following the combination.
